Clinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease.
Marc D S MoncrieffSerigne N LôRichard A ScolyerMartin J HeatonJenny P NobesAndrew P SnellingMichael J CarrCarolyn NessimRyckie George WadeA Howard PeachRumi KisyovaJennifer MasonEwan D WilsonGrant Switzer NolanRowan Pritchard JonesIva JohanssonRoger Olofsson BaggeLucie J WrightNakul G PatelVernon K SondakJohn F ThompsonJonathan S ZagerPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Patients with AJCC IIIA melanoma with SN tumor deposits ≥ 0.3 mm in maximum dimension are at higher risk of disease progression and may benefit from adjuvant systemic therapy or enrollment into a clinical trial. Patients with SN deposits < 0.3 mm in maximum dimension can be managed similar to their SN-negative, AJCC IB counterparts, thereby avoiding regular radiological surveillance and more intensive follow-up.